查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941555

心房颤动市场规模、份额和趋势分析报告：按疗法、最终用途、地区和细分市场预测（2026-2033 年）

Atrial Fibrillation Market Size, Share & Trends Analysis Report By Treatment (Pharmacological Treatment, Non Pharmacological Treatment), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

心房颤动市场概览

2025年全球心房颤动市场规模估计为295.2亿美元，预计2033年将达到653.3亿美元。

预计从 2026 年到 2033 年，该市场将以 10.52% 的复合年增长率成长。推动该市场成长的因素包括疾病负担加重、治疗和诊断技术的快速发展以及向远端患者监护的转变。

能够将这些先进技术整合到综合护理解决方案中的公司，并有望主导市场成长，因为临床实践正在向更有效率、以患者为中心的模式转型。旨在扩大创新疗法应用范围的策略联盟和收购将进一步加剧市场竞争。

人口老化以及高血压、糖尿病和肥胖等风险因素的增加，导致心房颤动盛行率不断上升，这是市场成长的关键驱动因素。心房颤动是中风和心臟衰竭的主要原因之一，医疗系统优先考虑早期诊断和有效治疗。患者数量的增长直接推动了对药物治疗和先进介入疗法的需求。 2024年5月，美国疾病管制与预防中心（CDC）将心房颤动（心房颤动）列为美国最常见的需要治疗的心律不整。预计到2030年，美国房颤患者人数将达1,210万人。心房颤动每年导致约15.8万人死亡，约占中风病例的七分之一。

心导管电气烧灼术、三维电解剖标测和可穿戴心电图（ECG）监测等技术的进步正在提高心房颤动治疗的准确性和安全性。人工智慧（AI）在心律不整检测和治疗计画中的应用，实现了更快、更准确的诊断和标靶治疗。这些创新不仅为更多患者提供了治疗选择，还改善了治疗效果并降低了復发率。据美国心律学会（HRS）称，在2025年4月举行的「心律2025」会议上发表的新研究表明，人工智慧（AI）正在提高心房颤动（AFib）治疗的安全性和成功率。人工智慧驱动的DeePRISM模型能够在消融手术过程中进行即时波形分析，进而改善持续性心房颤动患者的治疗效果。专家强调了人工智慧透过提高临床信心和手术准确性来改变电生理学的潜力。

远端监测和远端医疗平台的应用正在改变心房颤动的管理方式，使临床环境以外的持续心律监测成为可能。穿戴式心电图设备和智慧型手机应用程式可为患者和医生提供即时数据，从而支援主动管理和早期疗育。医疗服务提供者正在利用这些工具有效地监测更多患者，尤其是在术后追踪和长期照护方面。 2025年5月，墨尔本脑中心的研究人员开发了人工智慧模型，该模型能够利用脑部MRI影像分析检测中风患者的无症状性心房颤动。这项技术在区分心房颤动相关性中风方面展现出较高的准确率（AUC 0.81），提供了一种非侵入性且高效的检测方法。透过识别需要进一步心臟评估的亚临床心房颤动病例，这种方法可能有助于更快诊断和更个人化的中风治疗。

丛集柱状图显示了1990年至2021年间美洲地区与心律不整相关的伤残调整寿命年（DALYs）和死亡率的逐步上升。 DALYs从每10万人117.14增至120.68，死亡率从每10万人4.18增加到4.84。这反映出医疗保健系统持续面临日益增长的压力，尤其是在早期检测和先进治疗机会仍然不均的地区。如果不采取有针对性的医疗保健政策来消除这些区域差异，预计未来几十年心房颤动的临床和经济负担将进一步加重。

心房颤动（心房颤动）是全球最常见的持续性心律不整，由于其与中风、心臟衰竭和死亡风险增加有关，因此为医疗保健系统带来了巨大挑战。儘管治疗方法不断进步，但由于人口老化和生活方式相关的危险因素，过去30年全球心房颤动盛行率增加了一倍以上。根据2025年7月出版的《柳叶刀区域健康美洲》杂誌，区域差异持续影响整个美洲大陆心房颤动的负担。美国心房颤动发生率和盛行率增幅最大，而加拿大则出现了年龄调整后的下降。中等收入国家占心房颤动病例的大多数，且在筛检能力有限的情况下，其发生率仍在上升。解决这些系统性差异对于减轻心房颤动在该地区日益严重的临床和经济影响至关重要。

目录

第一章调查方法和范围

第二章执行摘要

第三章 全球心房颤动市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关市场展望
  • 市场动态
  • 全球心房颤动市场分析工具
    • 产业分析：波特五力模型
    • PESTLE分析
  • 科技趋势
  • 案例研究分析

第四章 全球心房颤动市场細項分析（依治疗方法划分，2021-2033 年）

  • 定义和范围
  • 按疗法分類的市场份额分析（2025 年和 2033 年）
  • 2021-2033年全球心房颤动市场（依治疗方法划分）
  • 药物治疗
  • 非药物疗法

5. 全球心房颤动市场細項分析（依最终用途划分，2021-2033 年）

  • 定义和范围
  • 按最终用途分類的市场份额分析（2025 年和 2033 年）
  • 2021-2033年全球心房颤动市场（依最终用途划分）
  • 医院
  • 专科诊所
  • 其他的

6. 2021-2033年按地区分類的心房颤动市场细分

  • 2025年及2033年区域市占率分析
  • 区域市场概览
  • 区域市场概览
  • 2025年及2033年各地区心房颤动市场占有率：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第七章 竞争情势

  • 对主要市场参与企业近期趋势和影响的分析
  • 公司分类
  • 公司简介
    • AtriCure Inc.
    • Boehringer Ingelheim GmbH
    • Boston Scientific Corporation.
    • Bristol-Myers Squibb Corporation
    • Cardio Focus Inc.
    • Sanofi Aventis
    • Biosense Webster Inc.
    • Endoscopic Technologies Inc.
    • Abbott（St. Jude Medical Inc.）
    • Johnson &Johnson
Product Code: 978-1-68038-004-0

Atrial Fibrillation Market Summary

The global atrial fibrillation market size was estimated at USD 29.52 billion in 2025 and is projected to reach USD 65.33 billion by 2033, growing at a CAGR of 10.52% from 2026 to 2033. The market is driven by a growing disease burden, rapid technological evolution in treatment and diagnostics, and the shift toward remote patient monitoring.

Companies capable of integrating these advancements into comprehensive care solutions are likely to lead market growth as clinical practices adapt to more efficient and patient-centric models. Strategic collaborations and acquisitions aimed at expanding access to innovative therapies will further accelerate market competitiveness.

The rising prevalence of atrial fibrillation, driven by aging populations and an increase in risk factors such as hypertension, diabetes, and obesity, is a major factor driving market growth. Atrial fibrillation is one of the leading causes of stroke and heart failure, prompting healthcare systems to prioritize early diagnosis and effective management. The growing patient pool is directly increasing demand for pharmacological treatments and advanced interventional procedures. In May 2024, the CDC highlighted atrial fibrillation (AFib) as the most common heart arrhythmia treated in the U.S. The number of Americans affected by AFib is expected to rise to 12.1 million by 2030. AFib plays a role in roughly 158,000 deaths each year and contributes to about 1 in 7 stroke cases.

Technological advancements in catheter ablation, 3D electro-anatomical mapping, and wearable ECG monitors are enhancing the precision and safety of atrial fibrillation treatments. Integration of artificial intelligence in arrhythmia detection and procedural planning is enabling faster, more accurate diagnosis and targeted therapy. These innovations are expanding treatment options to more patients while improving procedural outcomes and reducing recurrence rates. In April 2025, according to the Heart Rhythm Society (HRS), new research unveiled at Heart Rhythm 2025 showcased how artificial intelligence (AI) is enhancing safety and success rates in atrial fibrillation (AFib) treatments. The AI-driven DeePRISM model enables real-time waveform analysis during ablation procedures, improving outcomes for patients with persistent AFib. Experts highlighted AI's potential to transform electrophysiology by boosting clinical confidence and procedural precision.

The adoption of remote monitoring and telehealth platforms is changing how atrial fibrillation is managed, allowing continuous rhythm monitoring beyond clinical settings. Wearable ECG devices and smartphone-linked applications are providing real-time data to both patients and physicians, supporting proactive management and early intervention. Healthcare providers are leveraging these tools to monitor larger patient populations efficiently, especially for post-procedural follow-up and long-term care. In May 2025, researchers from the Melbourne Brain Centre developed an AI model that can detect silent atrial fibrillation (AF) in stroke patients by analyzing brain MRI scans. The technology showed promising accuracy (AUC 0.81) in differentiating AF-related strokes, offering a non-invasive and efficient detection method. This approach could potentially accelerate diagnosis and personalize stroke care by flagging hidden AF cases needing further cardiac evaluation.

The clustered column chart highlights the incremental rise in atrial fibrillation-related disability-adjusted life years (DALYs) and death rates across the Americas from 1990 to 2021. DALYs increased from 117.14 to 120.68 per 100,000 and death rates rose from 4.18 to 4.84 per 100,000. This reflects a persistent and growing burden on healthcare systems, particularly in regions where access to early detection and advanced treatment remains uneven. Without targeted healthcare policies to bridge these regional disparities, the clinical and economic strain of atrial fibrillation is projected to intensify in the coming decades.

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, posing a substantial challenge to healthcare systems due to its association with stroke, heart failure, and elevated mortality risks. Despite advancements in treatment options, the global prevalence of AF has more than doubled over the past three decades, driven by aging populations and lifestyle-related risk factors. In July 2025, according to The Lancet Regional Health Americas, regional disparities continue to shape the burden of atrial fibrillation across the continent. The U.S. experienced the highest rise in AF incidence and prevalence, while Canada saw a decline after age adjustments. Middle-income countries account for the majority of AF cases, facing rising incidence rates with limited screening infrastructure. Addressing these systemic gaps is critical to mitigating AF's escalating clinical and economic impact in the region.

Global Atrial Fibrillation Market Report Segmentation

This report forecasts revenue growth and provides a global, regional, and country level analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global atrial fibrillation market report based on treatment, end use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmacological Treatment
    • Anti-arrhythmic Drugs
    • Anticoagulant Drugs
  • Non-Pharmacological Treatment
    • Catheter Ablation
    • Radiofrequency
    • HIFU
    • Cryoablation
    • Microwave
    • Laser
    • Maze Surgery
    • Electric Cardioversion
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment scope
    • 1.1.2. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. Research Assumptions
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End use outlook
  • 2.3. Competitive Insights

Chapter 3. Global Atrial Fibrillation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Global Atrial Fibrillation: Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTLE Analysis
  • 3.4. Technology Landscape
  • 3.5. Case Study Analysis

Chapter 4. Global Atrial Fibrillation Market Segment Analysis, By Treatment, 2021-2033 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Treatment Market Share Analysis, 2025 & 2033
  • 4.3. Segment Dashboard
  • 4.4. Global Atrial Fibrillation Market, by Treatment, 2021 to 2033
  • 4.5. Pharmacological Treatment
    • 4.5.1. Pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.5.2. Anti-arrhythmic Drugs
      • 4.5.2.1. Anti-arrhythmic drugs market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.5.3. Anticoagulant Drugs
      • 4.5.3.1. Anticoagulant drugs market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6. Non-Pharmacological Treatment
    • 4.6.1. Non-pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2. Catheter Ablation
      • 4.6.2.1. Catheter ablation market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.2. Radiofrequency
        • 4.6.2.2.1. Radiofrequency market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.3. HIFU
        • 4.6.2.3.1. HIFU market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.4. Cryoablation
        • 4.6.2.4.1. Cryoablation market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.5. Microwave
        • 4.6.2.5.1. Microwave market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.6. Laser
        • 4.6.2.6.1. Laser market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.3. Maze Surgery
      • 4.6.3.1. Maze surgery market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.4. Electric Cardioversion
      • 4.6.4.1. Electric cardioversion market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Global Atrial Fibrillation Market Segment Analysis, By End Use, 2021-2033 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. End Use Market Share Analysis, 2025 & 2033
  • 5.3. Segment Dashboard
  • 5.4. Global Atrial Fibrillation Market, by End Use, 2021 to 2033
  • 5.5. Hospitals
    • 5.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Specialty Clinics
    • 5.6.1. Specialty Clinics market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Atrial Fibrillation Market Segment Analysis, By Region, 2021- 2033 (USD Million)

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Regional Market Snapshot
  • 6.4. Atrial Fibrillation Market Share by Region, 2025 & 2033:
  • 6.5. North America
    • 6.5.1. North America atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Scenario
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. U.S. atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Scenario
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Canada atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Scenario
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Mexico atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.2. UK
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Scenario
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. UK atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Scenario
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Germany atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Scenario
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. France atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Scenario
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Italy atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Scenario
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Spain atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Scenario
      • 6.6.7.3. Competitive Scenario
      • 6.6.7.4. Norway atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key Country Dynamics
      • 6.6.8.2. Regulatory Scenario
      • 6.6.8.3. Competitive Scenario
      • 6.6.8.4. Sweden atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key Country Dynamics
      • 6.6.9.2. Regulatory Scenario
      • 6.6.9.3. Competitive Scenario
      • 6.6.9.4. Denmark atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Scenario
      • 6.7.1.3. Competitive Scenario
      • 6.7.1.4. Japan atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Scenario
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. China atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Scenario
      • 6.7.3.3. Competitive Scenario
      • 6.7.3.4. India atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Regulatory Scenario
      • 6.7.4.3. Competitive Scenario
      • 6.7.4.4. Australia atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Regulatory Scenario
      • 6.7.5.3. Competitive Scenario
      • 6.7.5.4. South Korea atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key Country Dynamics
      • 6.7.6.2. Regulatory Scenario
      • 6.7.6.3. Competitive Scenario
      • 6.7.6.4. Thailand atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Scenario
      • 6.8.1.3. Competitive Scenario
      • 6.8.1.4. Brazil atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Scenario
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. Argentina atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key Country Dynamics
      • 6.9.1.2. Regulatory Scenario
      • 6.9.1.3. Competitive Scenario
      • 6.9.1.4. South Africa atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key Country Dynamics
      • 6.9.2.2. Regulatory Scenario
      • 6.9.2.3. Competitive Scenario
      • 6.9.2.4. Saudi Arabia atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key Country Dynamics
      • 6.9.3.2. Regulatory Scenario
      • 6.9.3.3. Competitive Scenario
      • 6.9.3.4. UAE atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key Country Dynamics
      • 6.9.4.2. Regulatory Scenario
      • 6.9.4.3. Competitive Scenario
      • 6.9.4.4. Kuwait atrial fibrillation market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Profiles
    • 7.3.1. AtriCure Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Boehringer Ingelheim GmbH
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Boston Scientific Corporation.
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Bristol- Myers Squibb Corporation
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Cardio Focus Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Sanofi Aventis
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Biosense Webster Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Endoscopic Technologies Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Abbott (St. Jude Medical Inc.)
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Johnson & Johnson
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Atrial Fibrillation Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 4 Global Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 5 Global Atrial Fibrillation Market, By Region, 2021 - 2033, (USD Million)
  • Table 6 North America Atrial Fibrillation Market, By Country, 2021 - 2033, (USD Million)
  • Table 7 North America Atrial Fibrillation Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 8 North America Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 9 U.S. Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 10 U.S. Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 Canada Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 12 Canada Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13 Mexico Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 14 Mexico Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 15 Europe Atrial Fibrillation Market, by Country, 2021 - 2033, (USD Million)
  • Table 16 Europe Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 17 Europe Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 18 UK Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 19 UK Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Germany Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 21 Germany Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 22 France Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 23 France Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 Italy Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 25 Italy Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 26 Spain Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 27 Spain Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 28 Denmark Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 29 Denmark Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 Sweden Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 31 Sweden Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 32 Norway Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 33 Norway Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 37 Japan Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 38 Japan Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 China Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 40 China Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 41 India Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 42 India Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 43 Australia Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 44 Australia Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Thailand Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 46 Thailand Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 47 South Korea Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 48 South Korea Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 49 Latin America Atrial Fibrillation Market, by Country, 2021 - 2033, (USD Million)
  • Table 50 Latin America Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 51 Latin America Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Brazil Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 53 Brazil Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54 Argentina Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 55 Argentina Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Atrial Fibrillation Market, by Country, 2021 - 2033, (USD Million)
  • Table 57 Middle East & Africa Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 58 Middle East & Africa Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 59 South Africa Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 60 South Africa Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 62 Saudi Arabia Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 63 UAE Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 64 UAE Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 66 Kuwait Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Global atrial fibrillation market: outlook
  • Fig. 9 Global atrial fibrillation competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Ancillary market outlook
  • Fig. 12 Global atrial fibrillation market driver impact
  • Fig. 13 Global atrial fibrillation market restraint impact
  • Fig. 14 Porter's Analysis
  • Fig. 15 PESTLE Analysis
  • Fig. 16 Global atrial fibrillation market: Treatment movement analysis
  • Fig. 17 Global atrial fibrillation market: Treatment outlook and key takeaways
  • Fig. 18 Pharmacological treatment market estimates and forecast, 2021 - 2033
  • Fig. 19 Anti-arrhythmic drugs market estimates and forecast, 2021 - 2033
  • Fig. 20 Anticoagulant drugs market estimates and forecast, 2021 - 2033
  • Fig. 21 Non-pharmacological treatment market estimates and forecast, 2021 - 2033
  • Fig. 22 Catheter ablation market estimates and forecast, 2021 - 2033
  • Fig. 23 Radiofrequency market estimates and forecast, 2021 - 2033
  • Fig. 24 HIFU market estimates and forecast, 2021 - 2033
  • Fig. 25 Cryoablation market estimates and forecast, 2021 - 2033
  • Fig. 26 Microwave market estimates and forecast, 2021 - 2033
  • Fig. 27 Laser market estimates and forecast, 2021 - 2033
  • Fig. 28 Maze surgery market estimates and forecast, 2021 - 2033
  • Fig. 29 Electric cardioversion market estimates and forecast, 2021 - 2033
  • Fig. 30 Global atrial fibrillation market: End use movement analysis
  • Fig. 31 Global atrial fibrillation market: End use outlook and key takeaways
  • Fig. 32 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 33 Specialty clinics market estimates and forecasts, 2021 - 2033
  • Fig. 34 Others market estimates and forecasts, 2021 - 2033
  • Fig. 35 Global atrial fibrillation market: Regional movement analysis
  • Fig. 36 Global atrial fibrillation market: Regional outlook and key takeaways
  • Fig. 37 North America atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 U.S. atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Canada atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Mexico atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Europe atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 UK atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Germany atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Spain atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Norway atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Asia Pacific atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Japan atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 China atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 India atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Australia atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Korea atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Thailand atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Brazil atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Argentina atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 MEA atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Kuwait atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key company categorization
  • Fig. 89 Heat map analysis 2025